Evidence indicates that PD-1 inhibitors account for a higher incidence of all-grade (3.6% vs. 1.3%) and high-grade (1.1% vs. 0.4%) pneumonitis when compared to PD-L1 inhibitors [125]. This evidence concerns the gene CD274 and pneumonitis.